Matsumi A.a· Tomoda T.a,b· Terasawa H.a· Fujii Y.a· Yamazaki T.a· Uchida D.a· Matsumoto K.a· Horiguchi S.a· Tsutsumi K.a· Kato H.a

Author affiliations

aDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
bDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 12, 2022
Accepted: February 01, 2023
Published online: March 10, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Introduction: Ceftriaxone (CTRX) is known to occasionally cause pseudolithiasis. This condition is often observed in children; however, few studies have reported the incidence and risk factors for CTRX-associated pseudolithiasis. Methods: In this single-center retrospective study, we investigated the incidence of and risk factors for CTRX-associated pseudolithiasis in adults. All patients underwent computed tomography to confirm pseudolithiasis before and after CTRX administration. Results: The study included 523 patients. Pseudolithiasis was detected in 89 patients (17%). Data analysis showed that abdominal area-related biliary diseases at the site of infection (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.064–0.53, p = 0.0017), CTRX administration for >3 days (OR 5.0, 95% CI: 2.5–9.9, p < 0.0001), CTRX dose of 2 mg (OR 5.2, 95% CI: 2.8–9.6, p < 0.0001), fasting period >2 days (OR 3.2, 95% CI: 1.6–6.4, p = 0.0010), and estimated glomerular filtration rate <30 mL/min/1.73 m2 (OR 3.4, 95% CI: 1.6–7.5, p = 0.0022) were independent factors for pseudolithiasis. Conclusions: CTRX-associated pseudolithiasis may occur in adults and should be considered in the differential diagnosis in patients who develop abdominal pain or liver enzyme elevation after CTRX administration, particularly in patients with chronic kidney disease, in those who are fasting, in and those who receive high-dose CTRX therapy.

© 2023 S. Karger AG, Basel

References Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother. 1982;10(3):207–15. Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322(3):141–7. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041–89. Shalviri G, Yousefian S, Gholami K. Adverse events induced by ceftriaxone: a 10 year review of reported cases to Iranian pharmacovigilance centre. J Clin Pharm Ther. 2012;37(4):448–51. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27(6):469–527. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100(6):1665–70. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990;99(6):1772–8. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2(8625):1411–3. Kong MS, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi. 1996;19(1):50–4. Tsukagoshi S, Ishizawa K, Hirayanagi K, Nagamine S, Makioka K, Fujita Y, et al. Progressive pseudolithiasis associated with the intravenous administration of ceftriaxone in patients with central nervous system infections. Intern Med. 2017;56(23):3189–92. Biner B, Oner N, Celtik C, Bostancioğlu M, Tunçbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006;34(5):217–22. Soysal A, Eraşov K, Akpinar I, Bakir M. Biliary precipitation during ceftriaxone therapy: frequency and risk factors. Turk J Pediatr. 2007;49(4):404–7. Imafuku A, Sawa N, Sekine A, Kawada M, Hiramatsu R, Yamanouchi M, et al. Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction. Clin Exp Nephrol. 2018;22(3):613–9. Ubukata M, Ohsawa I, Suzuki H, Asao R, Nakamura Y, Nishida H, et al. Hemodialysis as a risk factor for ceftriaxone-associated pseudolithiasis in adults. Ther Apher Dial. 2020;24(4):393–9. Doi Y, Takii Y, Ito H, Jingu N, To K, Kimura S, et al. Usefulness of endoscopic managements in patients with ceftriaxone-induced pseudolithiasis causing biliary obstruction. Case Rep Med. 2017;2017:3835825. Sasaki O, Sugimura K, Shinoda M, Shinkai M. Asymptomatic ceftriaxone-associated pseudolithiasis. J Gen Fam Med. 2019;20(5):209–12. Miyamoto T, Ebihara T, Kozaki K. Ceftriaxone and pseudolithiasis in older people. Geriatr Gerontol Int. 2018;18(3):507–9. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61. Yoshida R, Yoshizako T, Katsube T, Kitagaki H. Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults. Jpn J Radiol. 2019;37(12):826–31. Murata S, Aomatsu T, Yoden A, Tamai H. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis. Pediatr Int. 2015;57(5):942–6. Cuzzolin L, Oggiano AM, Clemente MG, Locci C, Antonucci L, Antonucci R. Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough? Fundam Clin Pharmacol. 2021;35(1):40–52. Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother. 1990;34(6):1146–9. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet. 1989;2(8655):165. Cohen D, Appel GB, Scully B, Neu HC. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983;24(4):529–32. Article / Publication Details

First-Page Preview

Received: August 12, 2022
Accepted: February 01, 2023
Published online: March 10, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.